Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies upgrades Genel to 'buy', lifts price target

(Sharecast News) - Jefferies upgraded Genel to 'buy' from 'hold' on Wednesday and lifted the price target to 100p from 85p. It noted that the shares have been volatile in the past couple of months as various media reports suggesting an imminent Iraq-Türkiye export pipeline reopening have proved incorrect.

"Having initiated at hold, we now upgrade to buy, seeing re-opening risk as over-sold, and a solid balance sheet with net cash to remain above $100m throughout 2024 supported by local sales, even if exports do not restart," it said.

Jefferies said there are a number of catalysts this year which could impact Genel's share price: the resumption of exports via IraqTürkiye pipeline; clarity on the recovery of $107m of Kurdistan Regional Government (KRG) receivables; potential M&A; and a successful Miran & Bina Bawi arbitration result.

"While there may be upside to shares from catalyst successes, we believe long-term shareholder value is dependent on a resumption of pipeline exports and payments framework," it said.

"This should allow for more certainty in the company cash flows and optionality for growth via M&A, which we believe is a key variable for E&P stock performance."

At 1040 GMT, the shares were up 2.2% at 84.82p.

Share this article

Related Sharecast Articles

Sirius Real Estate ups dividend as profits jump 32%
(Sharecast News) - Profits at business and industrial parks developer Sirius Real Estate surged by nearly a third in the year ended 31 March, helping the company to increase dividends for the tenth straight year.
GSK to appeal Delaware ruling on jury trials in Zantac cancer cases
(Sharecast News) - Pharma giant GSK said it would be appealing against a US court decision allowing jury trials in cases brought by cancer sufferers claiming its heartburn drug caused their condition.
AstraZeneca's lung cancer treatment recommended for approval in EU
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
China manufacturing PMI ticks up more than expected - Caixin
(Sharecast News) - Activity in China's manufacturing sector grew in May at the fastest rate in two years, according to data released on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.